News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
“One of our great strategic advantages is our compact and contiguous campus, where 12 amazing schools and a world-class health system coexist just a short walk from one another,” said Magill.
Penn spinout Vivodyne closed a $38 million seed funding round led by Khosla Ventures.
The goal of this platform is to engineer adoptive cell therapies inside of the body for specific autoimmune diseases.
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.
Cabaletta Bio received FDA clearance for their fourth Investigational New Drug application of CABA-201, their CAR T cell investigational therapy, to treat patients with generalized myasthenia gravis.
The goal was to discuss various topics related to technology commercialization, startup company formation, and building relationships between academia and the commercial sector.
The Philadelphia region has been designated as a federal innovation and technology hub, allowing it to compete for a grant of up to $75 million to advance its life sciences industry.
From American Sign Language to English to nature photography, Emily has a wide range of interests she intends to explore in her studies.